NCT07351773Completed
Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease
Autonomic Neuromodulation With Ultrasound-Guided Stellate Ganglion Block in Alzheimer's Disease: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if ultrasound-guided stellate ganglion block (SGB), added to standard drug treatment, can improve thinking and memory in people with Alzheimer's disease. It will also learn about the safety of SGB. The main questions this study aims to answer are: Do people who receive SGB plus standard drug treatment have better global cognition, measured by the Mini-Mental State Examination (MMSE), 1 month after finishing the treatment course compared with people who receive standard drug treatment alone? How do anxiety, depression, quality of life, and ability to live independently change over 1 month, 3 months, and 6 months after treatment? What medical problems, if any, occur during or after SGB? Researchers will compare two groups: SGB plus standard drug treatment Standard drug treatment alone Participants will: Be randomly assigned to one of the two groups Receive the assigned treatment Complete study visits and assessments at baseline and at 1 month, 3 months, and 6 months after finishing the treatment course
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 30 Dec 2025
- Start date
- 26 Jan 2025
- Primary completion date
- 29 Jun 2025
- Lead sponsor
- Taizhou Second People's Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT07351773
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 26 Jan 2025 to the primary completion date, 29 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cranial surgery or major head trauma within the past 6 months.
Other illness
- Known allergy to lidocaine, coagulation disorders, or other contraindications to stellate ganglion block (SGB).
- Severe cardiac, hepatic, or renal disease that could compromise safety.
- Cognitive impairment primarily due to other neurodegenerative diseases or psychiatric disorders.
Other
- Participation in other interventional trials that could affect study outcomes.
Who the study is looking for
- Age 55 to 85 years.
- Diagnosis of Alzheimer's disease (AD) based on the 2011 NIA-AA criteria.
- Mild to moderate cognitive impairment assessed by the Mini-Mental State Examination (MMSE).
- Ability to understand study procedures and provide written informed consent by the participant or a legally authorized representative.
- Ability to complete scheduled follow-up assessments.
Age in the registry: 55 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taizhou Second People's Hospital Coordinator of this site? Confirm its status | Taizhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.